Navigation Links
InterMune to Present at Citigroup Healthcare Conference
Date:5/16/2008

BRISBANE, Calif., May 16 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that John Hodgman, Senior Vice President and Chief Financial Officer of InterMune, will present at the Citigroup 2008 Global Healthcare Conference in New York on May 22, 2008 at 1:30 p.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... observed tiny quantum vortices in cold droplets of liquid ... that the exotic vortices arrange themselves as densely ... time that the quantum vortices, which have already been ... superfluid helium, have been detected in nanodroplets. "The experiment ... the University of Southern California, one of the experiment,s ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... Aug. 21, 2014 Telomere Biosciences, LLC ... Nutraceutical "TELO-20 for Dogs" with Telomerase Activation ... in the world for dogs. Telomeres are the ... in the body. A wealth of ground-breaking research ... Telomere Science and Aging, including Nobel laureates, has ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... Brazil and Mexico ... of several newly approved agents, the anticipated label ... and the launch of emerging biologics will substantially ... particular, the emerging IL-5 inhibitors will introduce a ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... Synthetic Biologics, Inc.  (NYSE Amex: ... and innovative disease-modifying medicines for serious illnesses, announced ... a Phase II clinical trial evaluating the efficacy ... of estriol (Trimesta™) for the treatment of relapsing-remitting ...
... JERICHO, N.Y., March 13, 2012   Health Care ... Via Christi Health System of Wichita, Kansas has ... rate just two months after selecting and implementing ... COI disclosure process. (Logo: http://photos.prnewswire.com/prnh/20061010/NYTU194LOGO ...
...  Good Shepherd Rehabilitation Network ( www.GoodShepherdRehab.org ), an ... and cognitive disabilities, today received the third Ekso ... called eLEGS) is a wearable, bionic robot by ... with lower-extremity paralysis or weakness to stand and ...
Cached Biology Technology:Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 2Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 3Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis 4Conflict of Interest Management System Selected by Via Christi Health 2Conflict of Interest Management System Selected by Via Christi Health 3Good Shepherd Rehabilitation Network Becomes Third Health-Care Organization in U.S. to Have Ekso Exoskeleton 2Good Shepherd Rehabilitation Network Becomes Third Health-Care Organization in U.S. to Have Ekso Exoskeleton 3
(Date:8/21/2014)... Carolina State University have developed a novel and versatile ... applications for creating new materials as well as for ... technique allows us to model much larger and more ... quickly," says Nan Li, lead author of a paper ... State,s Department of Materials Science and Engineering. "This is ...
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
(Date:8/20/2014)... Calif., August 19, 2014 -- Bay Area Lyme Foundation, ... and simple to cure, applauds new research published in ... Ticks and Tick-borne Diseases . The findings ... California are active throughout the year, making the threat ... researchers at California Department of Public Health (CDPH) Vector-borne ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... Toronto chemists have made a major contribution to the emerging ... photosynthesis in marine algae. "There,s been a lot of ... practices," says chemistry professor Greg Scholes, lead author of a ... "Our latest experiments show that normally functioning biological systems have ...
... mountains are thinning is not disputed. However, few researchers ... Lawrence Berkeley National Laboratory scientist Surabi Menon set out ... culpritgreenhouse gases, such as carbon dioxidefrom other particles in ... and her collaborators found that airborne black carbon aerosols, ...
... 3, 2010 For Immediate Release A team of ... that act on novel binding sites for an enzyme used ... AIDS. The discovery lays the foundation for the development of ... treat drug-resistant strains of the disease, and slow the evolution ...
Cached Biology News:Scientists find quantum mechanics at work in photosynthesis 2Black carbon a significant factor in melting of Himalayan glaciers 2Black carbon a significant factor in melting of Himalayan glaciers 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 2Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 4Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 5
... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_000314 ... Routinely evaluated by immunoblot. ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
CCNI Antibody...
...
Biology Products: